ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
Dec 20, 2022 12:01 JST
Source:
Eisai
Eisai to Divest Rights for Anti-Epileptic Drug Fycompa (perampanel) CIII in United States to Catalyst Pharmaceuticals
TOKYO, Dec 20, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has entered into an agreement to transfer the United States (U.S.) commercial rights for the anti-epileptic drug (AED) Fycompa (generic name: perampanel) CIII to Catalyst Pharmaceuticals, Inc., as well as to provide Catalyst Pharmaceuticals with an exclusive negotiation period for an asset in Eisai's epilepsy pipeline. Eisai will maintain its rights to Fycompa in countries and regions outside the U.S. and continue to contribute to patients with epilepsy. Closing of the transaction is contingent on completion of review under antitrust laws in the U.S.
The agreement will provide the opportunity for Eisai's neuroscience team to focus on its long-term strategic priorities on the research, development, and commercialization of its Alzheimer's disease portfolio. Eisai remains committed to drug discovery and research for anti-epileptogenesis through the modulation of neuroinflammation or lipid metabolism in glia cells, as well as the application of new technologies including spatial RNA-sequence. Research is a crucial aspect of Eisai's aim to gain a deeper understanding of human brain biology and technologies that may also ultimately lead to broader neuroscience discoveries.
In the U.S., Fycompa was approved in 2012 and has been prescribed to more than 50,000 patients. Catalyst Pharmaceuticals is a company focused on developing therapies for rare neuromuscular as well as neurological disorders, and is increasing its presence in neurology in the U.S. The agreement is expected to maximize the patient value of Fycompa in the U.S. due to its strong commitment to patients living with epilepsy.
Under the terms of the agreement, Eisai will receive a contractual up-front payment of $160 million (USD) upon closing of the transaction. In addition, milestone payments and royalties may be received in the future. Eisai will continue to be responsible for the manufacture and supply of Fycompa to global markets including the U.S. Eisai's U.S. subsidiary Eisai Inc. will provide transition services for a period to ensure patients continue to have access to this important medicine.
As a result of this transaction, Eisai anticipates no changes to its consolidated financial forecast for the period ended March 31, 2023.
Driven by our hhc concept, Eisai strives to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas: Neurology, Oncology and Global Health. As an hhceco company, Eisai aims to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities by creating solutions through building an ecosystem in collaboration with other industries.
About Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals, Inc. (Catalyst Pharmaceuticals) is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases. With exceptional patient focus, Catalyst Pharmaceuticals is committed to developing a robust pipeline of cutting-edge, best-in-class medicines for rare diseases. Catalyst Pharmaceuticals' New Drug Application for FIRDAPSE (amifampridine) Tablets 10 mg for the treatment of adults with Lambert-Eaton myasthenic syndrome ("LEMS") was approved in 2018 by the U.S. Food & Drug Administration ("FDA") and FIRDAPSE is commercially available in the U.S. as a treatment for adults and children ages six to seventeen with LEMS. Further, Canada's national healthcare regulatory agency, Health Canada, has approved the use of FIRDAPSE for the treatment of adult patients in Canada with LEMS.
Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120
Eisai Inc. (U.S.)
Christopher Vancheri
Christopher_vancheri@eisai.com
551-305-0050
Source: Eisai
Sectors: Healthcare & Pharm
Copyright ©2025 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Latest Release
Adyen and JCB launch Card-on-File Tokenization to Enhance Payment Security
May 13, 2025 11:00 JST
TOYOTA GAZOO Racing fights back for double points finish
May 12, 2025 15:45 JST
JCB and Arab Bank launch JCB merchant acquiring operations across Jordan
May 12, 2025 11:00 JST
Mitsubishi Heavy Industries Achieves Highest-Ever Order Intake, Revenue, Net Income, and Free Cash Flow in FY2024, Increases Dividends, and Releases FY2025 Guidance
May 09, 2025 18:57 JST
Valuufy Selected by Global Tech Leader for Environmental Impact Assessment
May 09, 2025 18:00 JST
Mazda Adopts North American Charging Standard for BEVs launched in Japan
May 09, 2025 16:03 JST
Mitsubishi Motors to Launch an All-New BEV Based on Nissan's Next-Generation LEAF in North America in the Second Half of 2026
May 08, 2025 11:25 JST
Mitsubishi Motors and Foxtron Sign MOU for OEM Supply of EV
May 08, 2025 11:08 JST
Everest Medicines Announces NMPA Full Approval of NEFECON, Broadening Treatment Access for IgA Nephropathy Patients in China
May 07, 2025 19:06 JST
Anime Tokyo Station: Mobile Suit Gundam GQuuuuuuX -Beginning- Special Exhibition
May 03, 2025 03:00 JST
TOYOTA GAZOO Racing Set for Spa spectacle
May 02, 2025 19:29 JST
FWD Group reports exceptionally strong first quarter new business update
May 02, 2025 17:00 JST
Toyota Mobility Foundation, Bangkok Metropolitan Administration, UN-Habitat, Asian Institute of Technology and Toyota Motor Thailand Sign a Letter of Intent (LOI) to Launch the TRUST Project for Road Safety in Thailand
May 01, 2025 17:48 JST
Katalon Officially Launches TrueTest(TM) - The First AI-Native Testing System That Thinks Like a Tester and Learns from Users
Apr 30, 2025 17:20 JST
Eisai Representative Corporate Officer and CEO Haruo Naito Awarded the Order of the Rising Sun, Gold and Silver Star
Apr 30, 2025 14:17 JST
Mitsubishi Shipbuilding Holds Christening and Launch Ceremony of Large Car Ferry KEYAKI in Shimonoseki
Apr 29, 2025 17:24 JST
NEC DGDF Headquarters relocates to Zurich to accelerate growth and enhance management globally
Apr 28, 2025 16:03 JST
NEC achieves Japan's longest terrestrial wireless optical communication over 10 km
Apr 25, 2025 17:50 JST
Olympus Appoints New CEO
Apr 25, 2025 15:30 JST
DENSO Announces Year-End Financial Results
Apr 25, 2025 12:17 JST
More Latest Release >>
Related Release
Eisai Representative Corporate Officer and CEO Haruo Naito Awarded the Order of the Rising Sun, Gold and Silver Star
4/30/2025 2:17:00 PM JST
Leqembi (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer's Disease to be Authorized in the European Union
4/18/2025 4:52:00 PM JST
Eisai to Divest Rights for Pariet in China to Peak Pharma
4/1/2025 1:15:00 PM JST
World's First Early Alzheimer's Disease Treatment Developed in Japan LEQEMBI Receives Prime Minister's Award at the 12th Technology Management and Innovation Awards
3/25/2025 5:28:00 PM JST
Eisai Selected as a Nadeshiko Brand 2025 as a Listed Company Excelling in Promotion of Women in the Workplace
3/25/2025 12:21:00 PM JST
Eisai Recognized as "2025 Kenko Investment for Health" for the First Time and Certified as "Outstanding Organization Of Kenko Investment for Health Program (White 500)" for the Sixth Time
3/10/2025 8:24:00 PM JST
Eisai: Update on the Co-Promotion of the Oral Antifungal Agent Nailin Capsules 100mg in Japan
3/5/2025 9:09:00 AM JST
Eisai Receives Regulatory Review Outcome for Lecanemab as a Treatment for Early Alzheimer's Disease in Australia
3/4/2025 5:22:00 PM JST
"Fatigue Recovery While You Sleep!" Eisai to Launch Designated Quasi-Drug Drink "Chocola BB Nightwell"
3/3/2025 3:41:00 PM JST
The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer's Disease
3/3/2025 1:53:00 PM JST
More Press release >>